1 / 21

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma. Site Specific Approaches, 2008 Lori J. Wirth, MD Dana-Farber Cancer Institute. Nasopharyngeal Carcinoma A Particularly Unique Entity in Head and Neck Cancers. Epidemiologic features Endemic pattern, EBV association

harper
Télécharger la présentation

Nasopharyngeal Carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nasopharyngeal Carcinoma Site Specific Approaches, 2008 Lori J. Wirth, MD Dana-Farber Cancer Institute

  2. Nasopharyngeal CarcinomaA Particularly Unique Entity in Head and Neck Cancers • Epidemiologic features • Endemic pattern, EBV association • Southern China, Southeast Asia, Northern Africa, Mediterranean basin, Inuit peoples, Caribbean

  3. Nasopharyngeal CarcinomaA Particularly Unique Entity in Head and Neck Cancers • Anatomic features present unique treatment challenges • Surgery • Radiotherapy

  4. Nasopharyngeal CarcinomaA Particularly Unique Entity in Head and Neck Cancers • NPC is more sensitive to both chemotherapy and radiotherapy compared to other head and neck cancers • But paradoxically more likely to involve lymph nodes and spread distantly

  5. Up-Front NPC Treatment • There is agreement that concurrent chemoradiotherapy is the best approach to locally advanced NPC • Role of chemotherapy – radiation sensitization, locoregional control • Also of interest – chemotherapy to treat micrometastatic disease and reduce the risk of distant metastasis • Here’s where the controversy lies • What is the optimal chemotherapy sequencing/schedule? • What is the optimal chemotherapy regimen?

  6. Up-Front NPC Treatment • At least 15 RCTs involving chemotherapy and radiotherapy in NPC • 4 meta-analyses performed • Still no broad consensus • Inconsistent results from similar studies • Studies involved different patient populations • Variable EBV-association • Dominant WHO histologies vary • Ethnicity • Different staging systems • Different treatments-chemo and radiotherapy • Less than ideal study design

  7. U.S. Intergroup 0099 cis PF RT 193 of 270 pts enrolled RT Al-Sarraf, JCO, 1998

  8. U.S. Intergroup 0099 • 3Y PFS 69% (CRT) vs. 24% (RT alone), p<0.001 • 3Y OS 78% (CRT) vs. 47% (RT alone), p=0.005 • Local control & distant mets also improved

  9. U.S. Intergroup 0099 • Issues • Flawed study design • Are the benefits from chemo due to concurrent administration, adjuvant, or both? • Terminated early after interim analysis showed survival benefit • RT alone arm performed worse than expected • Old RT techniques • Many patients enrolled had WHO type I NPC (not EBV-associated) • Adjuvant PF chemotherapy only feasible in some patients

  10. What’s Wrong with Adjuvant PF?

  11. Subsequent Asian Trials Contradictory

  12. Meta-analysis in NPCMAC-NPC Collaborative Group • To assess the impact of adding chemotherapy to RT on survival • 8 trials, 1753 pts • HR for death=0.82 (95% CI 0.71-0.95) • 6% absolute survival benefit at 5 years • Greatest benefit from concurrent chemo • HR=0.60 (concurrent) • HR=0.97 (adjuvant) • HR=0.99 (induction) • Baujat, IJROBP, 2006

  13. Meta-analysis in NPCMAC-NPC Collaborative Group • Conclusions • Chemotherapy added to RT in NPC yields a small but statistically significant improvement in survival • Benefit almost entirely from concurrent chemotherapy • However • Heterogeneity of studies, patients, chemotherapy regimens, and radiotherapy techniques limits lessons learned • No clear chemotherapy regimen superior to others • e.g. Al-Sarraf, PFL induction, bleo/epi/cis induction, concurrent UFT, adjuvant PF alternating with vincr/bleo/mtx • More effective chemotherapy regimens may exist

  14. Shift From Adjuvant to Induction Chemotherapy • Chua, IJROBP, 2006 • Subgroup analysis of 2 induction studies with cis/epirubicin and cis/bleo/5FU  RTvs. RT alone • Early stage pts (T1-2N0-1, st. IIB) had fewer distant mets with induction and improved survival • Yau, Head and Neck, 2006 • Phase II study of gemcitabine/cis X3  cis/accelerated concomitant boost RT • 3Y OS = 76%, 3Y PFS = 63% • Chan, JCO, 2004 • Phase II study of carbo/paclitaxel X2  cis/RT • Overall CR rate=97% • 2Y OS = 92%, 2Y PFS = 79%

  15. NPC Trials Currently Underway • Hong Kong • Randomized trial of adjuvant gem/cis in pts with elevated EBV titers following RT or CRT • Randomized trial of induction vs. adjuvant PF with concurrent CRT (cis/RT) • Induction PF  cis/radiation (Lee, IJROBP, 2005) • Well-tolerated, 92% completed all chemo, 96% completed radiation • 3Y PFS 75%, OS 71% • also compares capecitabine to 5FU • and accelerated concomitant boost RT to conventional fractionation • RTOG 0615 • Phase II study of concurrent bevacizumab/cis/RT  bevacizumab/PF X3

  16. Targets for Targeted Therapy in NPC • Numerous molecular determinants identified • EGFR, VEGF, survivin, CDKs • All overexpressed, prognostic, druggable targets • High-throughput screening underway to identify more druggable targets • EBV • Causal in >80% NPC cases worldwide • EBV found in every NPC cell • Clonal • EBV present in nasopharyngeal carcinoma in situ EBV-encoded RNA (EBER) in situ hybridization

  17. EBV as a Therapeutic Target in NPC • EBV proteins represent ideal non-self targets for cancer immunotherapy • EBV-associated NPC must somehow emerge by escaping the patient’s viral immune surveillance • Restoration or supplementation of EBV immunity by immunotherapy should be effective treatment

  18. Proof of Principle • Rooney, Blood, 1998 • Prophylactic treatment with EBV-specific T cells prevented PTLD (0/63 vs. 11.5% in historical controls) • Therapeutic treatment with EBV-specific T cells successful in 4/5 patients with established PTLD EBV-Specific Immunotherapy in Post-Transplant Lymphoproliferative Disorder Donor PBMCs Donor PBMCs EBV Repeated wkly stimulations EBV-infected lymphoblastoid cell line (LCL) EBV-Specific Cytotoxic T Cell (CTL)Product

  19. EBV-Specific Immunotherapy in NPC • Straathoff, Blood, 2005

  20. EBV-Specific Immunotherapy in NPCNumerous Challenges • Mismatch between viral gene expression & CTL specificity • Longevity of infused CTL • T cell depletion in immunocompromised PTLD host vs. “full tank” in NPC • CTL precursor frequency • Quality of immune response in cancer patients • Homing to mucosal tumor site • Tumor milieu • T cell infiltrates (lymphoepithelioma) contain suppressive T regulatory cells • What are the determinants for clinical efficacy? • T cell product • LMP2 and/or EBNA-1 CTL? • Tumor phenotype • LMP2 protein expression? • 100% of tumors express RNA, but only 50% express protein

  21. Statements on NPCMaximizing Treatment Approaches Now and Into the Future • Room for improvement to Al-Sarraf regimen • Concurrent platinum-based chemotherapy with definitive radiation should remain the mainstay of treatment • With rates of DM exceeding 20%, we need more effective systemic therapy than adjuvant PF • Induction regimens theoretically preferential to adjuvant • Highly effective regimens, such as taxane/platinum/5FU, are understudied • More exploration of targeted therapy added to definitive treatment also warranted • EBV-specific immunotherapy is a potentially useful treatment modality

More Related